Press
F-CRIN
26 May 2026
-
StrokeLink
Welcome to our website, where you will find all the information about our network.
Enjoy your visit! -
Asundexian for secondary prevention in stroke
The results of the OCEANIC STROKE trial by BAYER are positive : Among patients with noncardioembolic ischemic stroke or high-risk TIA treated with antiplatelet therapy, asundexian at a daily dose of 50 mg resulted in lower risks of ischemic stroke and major cardiovascular events than placebo, without a higher risk of major bleeding.
-
The ranking by Le Point
Le Point magazine reveals the ranking of hospitals that carried out at least twelve stroke-related hospitalizations in 2023 — and the StrokeLink network is included among the evaluation criteria, a sign of recognition and excellence.
-
Results of the OPEN WINDOW study
A multicenter observational study in which the authors compared the outcomes of patients who did or did not receive intravenous thrombolysis before being transferred to a thrombectomy centre.
This work is also the first achievement of StrokeLink’s PRIMO thematic group, representing a major step toward integrating stroke units without thrombectomy capabilities into our network.
StrokeLink in a few lines
StrokeLink is a French national multidisciplinary clinical research network specialising in stroke. Based on fundamental knowledge of stroke pathophysiology, multi-source databases and a network of clinical investigation centres, StrokeLink aims to reinforce France’s position as a leader in major trials and test therapies in early-phase trials to improve stroke care, from the acute to the chronic stages of the disease.
43%
of projects with an international scope
685
research projects involving F-CRIN
51%
of projects conducted with an industrial partners
1,348
publications mentioning F-CRIN or its components
Map of the network
The StrokeLink network centres are spread out across France. Click on the button to view where they are located.
News
Press
F-CRIN
07 April 2026
News
F-CRIN
12 March 2026
